Biodexa Pharmaceuticals (BDRX) AI Stock Analysis

• Market Cap: $1.51M
• Dividend Yield: N/A
• Average Volume (3M): 260.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: -100.00%
• EPS Growth: 86.75%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 648,314
• 10 Day Avg. Volume: 685,915
• 30 Day Avg. Volume: 260,967
• PEG Ratio: <0.01
• Price to Book (P/B): 0.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.09
• Enterprise Value/Market Cap: -5.30
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 4.68
• Enterprise Value/Ebitda: 0.93
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $3.50 ▲(50.21% Upside)
• Action: Reiterated Date: 04/07/26
• Date: Action: Reiterated 04/07/26

The score is held down primarily by ongoing losses, zero revenue, and continued cash burn despite improvement in 2025. Technicals also remain weak with negative MACD and the price below longer-term moving averages, while valuation is difficult to support due to a negative P/E and no dividend yield. The key positive is a low-debt balance sheet with increased equity, which partially mitigates funding risk.

Positive Factors

Low leverage / stronger balance sheet

A very low debt load and meaningful equity growth provide financial flexibility for a clinical-stage firm. This reduces near-term solvency risk, lowers interest burden, and gives management optionality to fund trials or pursue partnerships without immediate debt constraints, supporting multi-quarter development plans.

Negative Factors

Zero revenue and persistent losses

Absent product revenue, the company lacks internal earnings to fund operations; persistent operating losses mean ongoing reliance on capital markets or partners. If development timelines slip, prolonged losses could erode equity and limit strategic choices, making the business model dependent on external funding.

Biodexa Pharmaceuticals Business Overview & Revenue Model

Company Description

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan canc...

Read more

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan canc...

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Biodexa has historically not generated material recurring revenue from marketed pharmaceutical product sales (null). Its operations have primarily been funded through financing activities such as the ...

Read more

As a clinical-stage biopharmaceutical company, Biodexa has historically not generated material recurring revenue from marketed pharmaceutical product sales (null). Its operations have primarily been funded through financing activities such as the ...

Biodexa Pharmaceuticals Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	381.00K	699.00K	578.00K
Gross Profit	-184.86K	-5.44M	-3.69M	-4.41M	-4.08M
EBITDA	-8.08M	-9.08M	-7.16M	-8.26M	-5.66M
Net Income	-6.24M	-5.73M	-7.08M	-7.66M	-5.46M
Balance Sheet
Total Assets	18.15M	14.78M	10.54M	5.53M	12.91M
Cash, Cash Equivalents and Short-Term Investments	8.52M	1.67M	5.97M	2.84M	10.06M
Total Debt	60.89K	727.00K	464.00K	624.00K	766.00K
Total Liabilities	6.76M	6.46M	5.86M	2.36M	2.46M
Stockholders Equity	11.38M	8.32M	4.68M	3.16M	10.45M
Cash Flow
Free Cash Flow	-5.40M	-13.04M	-7.09M	-7.11M	-6.33M
Operating Cash Flow	-5.39M	-12.26M	-6.83M	-7.05M	-6.01M
Investing Cash Flow	-658.25K	-598.00K	-265.00K	-220.00K	-278.00K
Financing Cash Flow	12.77M	8.56M	10.23M	47.00K	8.80M

Biodexa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Negative. The current price of 2.33 is below the 20-day moving average (MA) of 3.71, below the 50-day MA of 5.45, and below the 200-day MA of 24.38, indicating a bearish trend. The MACD of -0.63 indicates Negative momentum. The RSI at 38.18 is Neutral, neither overbought nor oversold. The STOCH value of 22.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDRX.

Biodexa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDRX	43 Neutral	$1.51M	-0.07	-63.03%	―	-100.00%	86.75%
INDP	42 Neutral	$3.59M	-0.13	-317.98%	―	―	34.57%
INM	42 Neutral	$1.99M	―	-82.17%	―	-3.27%	51.83%
ENVB	42 Neutral	$3.68M	-0.10	-262.78%	―	―	79.45%
CNSP	42 Neutral	$1.77M	-0.15	-197.11%	―	―	99.87%

Biodexa Pharmaceuticals Corporate Events